Current informed consent forms should be expanded to address the unique vulnerabilities experienced under the effects of psychedelics to ensure participants are fully informed of potential risks.

While psychedelic-assisted therapy shows promise, further research is needed to understand its safe and effective use in clinical populations, considering the differing interests of non-clinical stakeholders.

Around 7% of psychedelic users may experience permanent and unwanted personality changes, including increased anxiety.

In a study of 770 Norwegian psychedelic drug users, 23% experienced adverse effects lasting more than a day, with 10% lasting days, 4.5% weeks, 3.8% months, and 4.2% over a year, while 25% reported mostly mild flashbacks.

Lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history

Group and solo psychedelic use report similar mental health benefits with rare negative outcomes, highlighting the potential for safe, communal use settings in harm reduction strategies

Negative psychological responses to psychedelics, including new or worsened psychiatric symptoms, can occur, particularly in unsafe or complex environments, with high or unknown drug quantities, or in individuals with prior psychological vulnerabilities or young age, highlighting the need for careful use and risk-mitigation strategies.

Psychedelic-assisted psychotherapy, including therapies with MDMA and ketamine, may be beneficial for individuals with psychopathological psychosis and psychotic conditions, provided they have high levels of support and the right conditions, but further research is needed to assess risks and develop specific protocols.

Around 7% of individuals may experience negative effects lasting 2-3 months after using magic mushrooms in a naturalistic setting.

Psychedelic use among healthcare providers treating psychiatric disorders has been associated with improvements in depression, anxiety, well-being, and resilience, and a decrease in suicidality, suggesting potential benefits despite 13.2% reporting at least one harm.